| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6417175 | ALLERGAN | Phosphonocephem derivatives, process for the preparation of the same, and use thereof |
Apr, 2022
(1 year, 5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629861 | ALLERGAN | Compositions and methods for treating bacterial infections using ceftaroline |
Sep, 2030
(6 years from now) | |
| US8247400 | ALLERGAN | Cephem compounds useful for the treatment of bacterial infections |
Feb, 2031
(7 years from now) | |
Teflaro is owned by Allergan.
Teflaro contains Ceftaroline Fosamil.
Teflaro has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Teflaro are:
- US6417175
Teflaro was authorised for market use on 29 October, 2010.
Teflaro is available in powder;intravenous dosage forms.
Teflaro can be used as methods for treating bacterial infections, method of treating bacterial infections.
The generics of Teflaro are possible to be released after 10 February, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Sep 13, 2022 |
Drugs and Companies using CEFTAROLINE FOSAMIL ingredient
Market Authorisation Date: 29 October, 2010
Treatment: Method of treating bacterial infections; Methods for treating bacterial infections
Dosage: POWDER;INTRAVENOUS
TEFLARO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic